Cala Health has received FDA clearance for the Cala kIQ Plus system, a next-generation wearable neurostimulation device aimed at alleviating action hand tremors associated with essential tremor and Parkinson’s disease. This device features innovative therapy modes and adaptive calibration that enhance tremor relief while personalizing treatment for users, ultimately providing a more intuitive experience during episodes of tremor.

The significance of the kIQ Plus system lies in its potential to improve patient outcomes through optimized tremor control. Preliminary clinical data, to be presented at the upcoming American Academy of Neurology meeting, indicates promising results, including increased responder rates and bilateral tremor improvement in patients with essential tremor. This suggests that the kIQ Plus may not only enhance the quality of life for individuals suffering from these conditions but also offers a significant advancement in non-pharmacological interventions for managing tremors, which are often challenging to treat effectively.

The takeaway from this development is the potential shift in treatment paradigms for essential tremor and Parkinson’s disease. With the kIQ Plus being available through the Veterans Affairs Health System and covered by Medicare for qualifying patients, this could accelerate the integration of wearable neurostimulation devices into standard care protocols. As research continues to validate its efficacy, the kIQ Plus may influence future drug development timelines and strategies, prompting a reevaluation of how we approach tremor management in clinical settings.

Source: longevity.technology